# Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

> **NCT07027748** · PHASE1 · RECRUITING · sponsor: **Steven DuBois, MD** · enrollment: 18 (estimated)

## Conditions studied

- Neuroblastoma
- Neuroblastoma Recurrent
- Relapsed Neuroblastoma
- Refractory Neuroblastoma

## Interventions

- **DRUG:** Naxitamab
- **DRUG:** Irinotecan
- **DRUG:** Temozolomide
- **DRUG:** Sargramostim granulocyte-macrophage colony stimulating factor

## Key facts

- **NCT ID:** NCT07027748
- **Lead sponsor:** Steven DuBois, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-27
- **Primary completion:** 2026-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07027748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07027748, "Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07027748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*